Latest News

Allergist Juanita Mora, MD, breaks down the ALA's COVID-19 prevention campaign — who needs a booster now, and how specialists can close the gap.

Hematology in July 2026: FDA priority review for Agios' mitapivat in sickle cell disease, plus Orca-T's approval for GVHD-free survival.

Merck's sBLA seeks to extend clesrovimab-cfor (Enflonsia) coverage to children under 2 years at increased risk for severe RSV during their second season.

Linda Stein Gold, MD, discusses age-stratified ADORING data on tapinarof cream for atopic dermatitis, presented at the 2026 SPD Annual Meeting.

The mRNA-based vaccine wins full approval for adults aged 50 to 64 years and accelerated approval for adults aged ≥ 65 years following unanimous VRBPAC backing.

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Linda Stein Gold, MD, discusses ADORING trial endpoints and remaining treatment gaps in the youngest patients with atopic dermatitis.

FDA approval is based on phase 3 FirstLight and RadiantLight trials, the first therapy to directly restore orexin signaling in adults with NT1.

Oral encapsulated FMT increased peanut reactivity thresholds in 6 of 15 adults, tied to RORγt+ Treg cell expansion.

A study found children with and without food allergy screen positive for possible ARFID at similar rates, Daniela Ciciulla, APD, CEDC, says.

The FDA approved a 12-hour OTC combination of guaifenesin, dextromethorphan, and naproxen for cold and influenza symptom relief.

Tomashefski discusses where AATD diagnoses go missed and why APPs are positioned to close the gap.

Centanafadine FDA approval, DT120 EMERGE trial results, and COMP360 psilocybin data headline this month's psychiatry coverage.

STOP-HS1 and STOP-HS2 data show povorcitinib nearly doubled treatment response rates versus placebo in moderate to severe HS.

Hepatology in July 2026: Odevixibat misses phase 3 primary endpoint, zabopegdutide shows early MASH benefit, plus a new Wilson disease NDA

This episode covers the recently announced topline data from the TRIUMPH-2 and TRIUMPH-3 phase 3 trials, as well as a study investigating online GLP-1 sales.

Highlights include an exploratory nerandomilast mortality analysis, the first North American bronchiectasis guideline from CHEST, and more.

The FDA has granted Fast Track designation to PVX108, Aravax's investigational peptide immunotherapy for peanut allergy, ahead of phase 2 data expected later in 2026.

Sibeprenlimab (Voyxact) achieves KDIGO goal, stabilizing eGFR decline in IgA nephropathy at 2-year Phase 3 VISIONARY readout.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia and the FDA approval of Furoscix ReadyFlow.

The conditional recommendations cover antibiotic therapy, long-term prevention strategies, airway clearance, and more.

Nephrology in July 2026: FDA approvals for atacicept, iptacopan, and Furoscix in IgAN/CKD, plus new IgAN and CKD trial data.

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.